I-Corps: Mini-Disc Point-of-Care Personalized Diagnostic Platform

I-Corps：迷你光盘护理点个性化诊断平台

• 批准号: 2330092
• 负责人: Lawrence Kulinsky
• 金额: $ 5万
• 依托单位: University of California-Irvine
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2330092&HistoricalAwards=false
• 关键词: Corps; Mini; Disc; Point; Care

The broader impact/commercial potential of this I-Corps project is a portable single cell electrokinetic separation platform for healtchare applications. It can be implemented in hospitals, medical offices, and laboratories to improve patient outcomes by allowing for a wide array of sample-to-answer biological tests. This is considered a personalized diagnostic and can be performed in doctors’ offices and at the patient bedside, including early diagnostic of circulating tumor cells or testing for sepsis or heart attack, and also for improving biopharmaceutical drug discovery and biosynthesis. This I-Corps project is based on the development of the electrokinetic micro- and nano-assembly process. The goal of the outlined technology development and commercialization project is to create a universal portable centrifugal microfluidic platform that will be applicable for a wide range of tests from general fluid chemistry assays to biomarker assays and single cell analysis. This platform could find widespread use in hospitals and medical offices as well as in scientific laboratories. The proposed compact microfluidic system unifies sample preprocessing capabilities possible on a centrifugal microfluidic platform with electrokinetic sorting, separation, and capture of biological cells and molecules. The proposing team has expertise, capability, and needed resources to undertake the technical development and commercialization of the proposed centrifugal microfluidic sample-to-answer platform.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛的影响/商业潜力是用于HealthChare应用程序的便携式单细胞电动分离平台。它可以在医院，医疗办公室和实验室中实施，以通过允许多种样本到答案的生物学测试来改善患者的预后。这被认为是个性化的诊断，可以在医生的办公室和患者的床边进行，包括早期诊断循环肿瘤细胞或测试脓毒症或心脏病发作，以及改善生物药物药物发现和生物合成。这个I-Corps项目基于电子微型和纳米组装过程的开发。概述的技术开发和商业化项目的目的是创建一个通用的便携式离心微流体平台，该平台将适用于从一般流体化学测定到生物标志物测定和单细胞分析的广泛测试。该平台可以在医院和医疗办公室以及科学实验室中找到广泛使用。提出的紧凑型微流体系统统一在离心微流体平台上样品预处理能力，具有电子分类，分离和生物细胞和分子的捕获。该提案团队具有专业知识，能力和所需的资源，以实现拟议的离心微流体样本到解答平台的技术开发和商业化。该奖项反映了NSF的法定任务，并被认为是通过基金会的知识分子优点和更广泛的影响审查标准来通过评估来获得的支持。